Research location
Jilin City
Changchun, China
Advertisement
Research activity in Jilin City
Changchun, ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 10 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Jilin City
9 linked trials · page 1 of 1A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.NCT07593027 · 2026-04-30 · 2 site observations
RECRUITING
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)NCT05427370 · 2023-06-22 · 1 site observation
RECRUITING
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationNCT05504278 · 2022-09-20 · 1 site observation
RECRUITING
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyNCT06924606 · 2025-07-15 · 1 site observation
TERMINATED
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerNCT06265428 · 2024-01-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy SubjectsNCT05497674 · 2022-02-21 · 1 site observation
COMPLETED
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.NCT03944499 · 2019-10-11 · 1 site observation
COMPLETED
Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast CancerNCT03959397 · 2019-06-01 · 1 site observation
UNKNOWN
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)NCT03711305 · 2018-12-30 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.